Therapy News and Research

RSS

Thermedical closes $1.5 million in Series A funding

Thermedical, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, today announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D.

21 Mar 2012

NCCN issues first ever clinical practice guidelines for ALL

The National Comprehensive Cancer Network has issued its first ever NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia.

21 Mar 2012

Cardium commences Generx Phase 3 registration study in myocardial ischemia

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.

21 Mar 2012

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.

21 Mar 2012

Electroconvulsive therapy and how it works in severe depression: Study

Electroconvulsive therapy, or ECT, has been used in severely and persistently depressed patients from their disabling mood state for more than seven decades. Researchers have searched for the reason why this technique sometimes works in these patients.

20 Mar 2012

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

RaySearch receives PMH contract for new adaptive radiation therapy solution

RaySearch Laboratories AB has been awarded a contract for a new adaptive radiation therapy solution at Princess Margaret Hospital (PMH) in Toronto, Canada. This means that RaySearch will deliver its treatment planning system RayStation to PMH where it will be used as the primary treatment planning tool for adaptive radiation therapy.

20 Mar 2012

EJSO publishes results from Cytori breast reconstruction cell therapy trial

Cytori Therapeutics announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.

20 Mar 2012

Fox Chase to present best practices in cancer survivorship at 17th NCCN conference

People are living longer with and after a cancer diagnosis, making survivorship clinics and programs-as well as official guidelines and practices governing the care of survivors-an important emerging component of modern cancer care. Many institutions are looking to gather these resources into an easily understandable plan for their survivors.

20 Mar 2012

Viewpoints: The argument for the health law; No one wins contraception battle

It's said that you can judge a man by the quality of his enemies. If the same principle applies to legislation, the Affordable Care Act - which was signed into law two years ago, but for the most part has yet to take effect - sits in a place of high honor.

20 Mar 2012

UAB to present at annual American College of Cardiology Scientific Sessions

The University of Alabama at Birmingham has a number of presentations and experts available to comment on news being presented at the annual American College of Cardiology Scientific Sessions that begin Saturday, March 23, 2012, in Chicago.

20 Mar 2012

Hedgehog and mTOR pathway are active in esophageal cancer

Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway.

20 Mar 2012

AstraZeneca, Targacept announce top-line results from remaining TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who did not respond adequately to initial antidepressant treatment.

20 Mar 2012

CJC publishes updated atrial fibrillation guidelines

The Canadian Journal of Cardiology has published a focused update to the Canadian Cardiovascular Society's atrial fibrillation guidelines.

20 Mar 2012

Two Cedars-Sinai physicians to receive ACC Distinguished Scientist Award

Two physicians from the Cedars-Sinai Heart Institute will receive the American College of Cardiology's highest honors for scientific research and clinical care during the organization's upcoming annual scientific meeting in Chicago.

20 Mar 2012

Researchers identify Wnt pathway as new target for scleroderma therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy.

20 Mar 2012

New three-step process for DMD newborn screening

Investigators at Nationwide Children's Hospital, working with the DNA Sequencing Core Facility at the University of Utah, have developed an approach to newborn screening (NBS) for the life-threatening genetic disorder, Duchenne muscular dystrophy (DMD) and potentially other muscular dystrophies.

20 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

AIDS survey preliminary data show stagnation in Uganda's HIV prevalence, need for improved prevention strategies, experts say

A preliminary report on the Uganda AIDS Indicator Survey, conducted by the Ministry of Health, shows the country's "HIV prevalence rate has stagnated over the last 10 years, and the number of people infected with HIV has risen from 1.8 million people to 2.3 million today," the Observer writes.

20 Mar 2012

Groundbreaking cystic fibrosis clinical trial to proceed after renewed funding

The team of scientists based in Edinburgh, Oxford and London were developing a treatment which involves putting genes into the lungs of patients suffering the fatal, inherited wasting disease, passed early clinical trials in 2010. But the recession badly affected the Cystic Fibrosis Trust, the charity that had funded the programme, and work had to stop last year just as the consortium was closing in on its goal.

19 Mar 2012